| Name | Title | Contact Details |
|---|
Empowering the industry with the resources, expertise, and capital to help accelerate the advancement and adoption of cell and gene therapies.
InCarda Therapeutics is a clinical stage drug delivery company pioneering a novel approach of treating cardiovascular diseases and conditions by the inhalation route.
At Travere Therapeutics, our mission is to identify, develop and deliver life-changing therapies to people living with rare disease. #InRareForLife
Apogee Therapeutics is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology indications with high unmet need. Apogee`s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. The company`s two most advanced programs are APG777 and APG808, which are being initially developed for the treatment of AD and COPD, respectively. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today`s standard of care.